Likarda

Executive Summary

Likarda is a Kansas City-based biotechnology company that offers the proprietary Core-Shell Spherification® (CSS®) platform, a versatile drug delivery and cell encapsulation technology. The CSS platform creates protective hydrogel shells around cells, biologics, or small molecules, enabling controlled and sustained release. By partnering with biotech and pharma organizations, Likarda solves formulation challenges across cell therapy, cryopreservation, and large and small molecule delivery. The company's technology has the potential to enhance therapeutic efficacy and patient outcomes across multiple modalities. Currently in the pre-clinical stage, Likarda is actively advancing its platform through research collaborations and internal development. The company's CSS technology is well-positioned to address key limitations in cell therapy and drug delivery, such as poor stability, immune rejection, and suboptimal release kinetics. While Likarda faces typical early-stage risks, its differentiated approach and strong IP position provide a solid foundation for growth. Successful validation of its platform in partnership with leading pharma or biotech could be a significant inflection point.

Upcoming Catalysts (preview)

• Q3 2026Announcement of New Pharma/Biotech Partnership for CSS Platform55% success
• Q4 2026Publication of Preclinical Data Demonstrating CSS Efficacy in Cell Therapy50% success
• Q1 2027Series A Funding Round to Advance Pipeline60% success